3D Medicines Inc.
Status: Publicly traded
Direct answer
3D Medicines Inc. is publicly traded on HKSE under the ticker 1244.HK.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via...
Can you invest in 3D Medicines Inc.?
Yes. 3D Medicines Inc. trades publicly on HKSE as 1244.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for 3D Medicines Inc.
Detailed equity research is provided by MarketSnap.